Navigation Links
Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
Date:11/12/2012

NATICK, Mass., Nov. 12, 2012 /PRNewswire/ -- Karyopharm Therapeutics Inc., leading the new field of nuclear transport modulators, announces an oral presentation on the use of its SINE CRM1 antagonists for the treatment of systemic lupus erythematosus.

Jennifer Anolik, MD, PhD, Associate Professor of Medicine, Department of Medicine at the University of Rochester (New York), is presenting "Novel nuclear export inhibitors deplete autoreactive plasma cells and protect mice with lupus from nephritis" at the ACR Annual Meeting in Washington DC on November 14 at 12:15 PM in the Concurrent Session on SLE Animal Models.  Dr. Anolik commented, "We are very excited about our findings with Karyopharm's SINE compounds in our mouse lupus models.  These mice develop severe lupus kidney disease which, if untreated, leads to their death.  When we treated the mice with SINE compounds given by mouth, we were able to reduce the level of kidney disease, associated pathogenic autoantibodies, and the plasma cells that produce them.  We are hoping that SINE compounds will be able to move into clinical studies in patients with lupus in the near future."

Dr. Sharon Shacham, Karyopharm's founder, Chief Scientific Officer, and President of research and development commented, "This presentation represents our first public announcement of activity of our novel, oral SINE compounds in an autoimmune disease.  We are particularly excited about Dr. Anolik's work pioneering the use of our compounds to treat mice with severe lupus, and look forward to additional work with her to clarify the key mechanisms responsible for the marked activity she has demonstrated.  We are working with Dr. Anolik and others on plans to evaluate these compounds in humans suffering from lupus and other autoimmune diseases."

About Karyopharm

Founded by Drs. Sharon Shacham and Michael Kauffman in 2009, Karyopharm Therapeutics Inc. has emerged as a leader in the new field of nuclear transport modulators.  The company's selective inhibitors of nuclear export (SINE) function by trapping multiple tumor suppressor and anti-inflammatory proteins in the nucleus, resulting in anti-cancer and anti-inflammatory activity. In collaboration with many academic laboratories, SINEs, targeting the major nuclear exporter CRM1, exert robust anti-cancer and autoimmune disease activity in diverse preclinical models. The lead SINE KPT-330 is now in Phase 1 clinical studies for advanced solid tumor and hematologic malignancies. The related SINE KPT-335 is being evaluated as an oral treatment for dogs with Non-Hodgkin's Lymphoma, one of the most common canine cancers.  The Company is also testing SINEs in other autoimmune diseases, as well as viral and dermatologic disorders. Karyopharm Therapeutics is located in Natick, Massachusetts.

Contact:
Michael Kauffman
(508)975-4821
mkauffman@karyopharm.com


'/>"/>
SOURCE Karyopharm Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
2. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
3. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
4. Nile Therapeutics Reports 2011 Third Quarter Financial Results
5. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
6. Fate Therapeutics Strengthens Its iPSC Platform
7. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
10. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
11. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2018)... ... September 12, 2018 , ... NDA Partners Chairman Carl ... Senior Director of Regulatory Affairs and Quality Systems at WellDoc, Inc., has joined ... Affairs and Quality Systems at WellDoc, Inc., she conducted quality control and supplier ...
(Date:9/7/2018)... ... September 06, 2018 , ... Akadeum Life Sciences today announced it ... as an executive and leader of numerous biotech companies. , He most recently ... company acquired by Thompson Street Capital in St. Louis, MO. Prior to ISTO, ...
(Date:8/29/2018)... ... ... Cognition Corporation ®, a software company specializing in medical device compliance and ... Ryan Ward, Director of Engineering at Zimmer Biomet, has been announced as a speaker ... Zimmer Biomet for almost 15 years, Mr. Ward will focus his talk about how ...
(Date:8/26/2018)... ... August 23, 2018 , ... LabRoots ... scientists from around the world, will host the 4th Annual Microbiology and Immunology ... industries and disciplines, encompassing various research areas including medicine, agriculture, and space. ...
Breaking Biology Technology:
(Date:8/29/2018)... ... 2018 , ... Johanna Dwyer, founder and Chief Executive Officer ... in the field of intellectual property, and named Daniela Sanchez as the 2018 ... aims to encourage and support women in their pursuit of careers in IP, ...
(Date:8/26/2018)... (PRWEB) , ... August 24, ... ... become an essential tool in clinical diagnostic laboratories. However, this technology introduces ... at Guy’s Hospital London, which leads the South London NHS Genomic Medicine ...
(Date:8/23/2018)... ... August 22, 2018 , ... RURO, Inc., an industry-leading ... of its rapidly growing cloud-based laboratory information system. , With the success of ... company’s triple digit growth throughout 2018, the RURO team has been hard at ...
Breaking Biology News(10 mins):